Axsome Other Current Assets vs Non Current Assets Total Analysis

AXSM Stock  USD 97.74  1.08  1.09%   
Axsome Therapeutics financial indicator trend analysis is way more than just evaluating Axsome Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Axsome Therapeutics is a good investment. Please check the relationship between Axsome Therapeutics Other Current Assets and its Non Current Assets Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Other Current Assets vs Non Current Assets Total

Other Current Assets vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Axsome Therapeutics Other Current Assets account and Non Current Assets Total. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Axsome Therapeutics' Other Current Assets and Non Current Assets Total is 0.96. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Axsome Therapeutics, assuming nothing else is changed. The correlation between historical values of Axsome Therapeutics' Other Current Assets and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Axsome Therapeutics are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Other Current Assets i.e., Axsome Therapeutics' Other Current Assets and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

0.96
Relationship DirectionPositive 
Relationship StrengthVery Strong

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from Axsome Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 12th of December 2024, Tax Provision is likely to grow to about 1 M, while Sales General And Administrative To Revenue is likely to drop 0.78.
 2021 2022 2023 2024 (projected)
Interest Expense5.7M7.3M6.5M6.8M
Depreciation And Amortization1.2M5.6M6.8M7.2M

Axsome Therapeutics fundamental ratios Correlations

0.830.860.860.71-0.8-0.740.810.870.870.420.480.870.750.850.89-0.060.510.430.410.590.840.790.550.820.84
0.830.980.980.5-0.77-0.970.950.930.930.590.680.940.981.00.96-0.220.670.540.230.780.920.860.021.01.0
0.860.980.990.62-0.72-0.940.950.890.890.510.610.980.961.00.94-0.180.610.480.150.70.970.920.120.980.99
0.860.980.990.57-0.77-0.960.980.920.920.580.680.970.960.990.96-0.180.680.530.230.770.970.930.110.980.99
0.710.50.620.57-0.2-0.340.450.360.36-0.21-0.120.690.410.560.440.12-0.08-0.1-0.24-0.050.670.640.660.50.56
-0.8-0.77-0.72-0.77-0.20.78-0.8-0.95-0.95-0.75-0.76-0.69-0.73-0.76-0.910.23-0.78-0.67-0.79-0.89-0.66-0.62-0.13-0.77-0.75
-0.74-0.97-0.94-0.96-0.340.78-0.98-0.92-0.92-0.73-0.82-0.9-0.98-0.96-0.940.28-0.8-0.62-0.29-0.88-0.91-0.880.12-0.97-0.95
0.810.950.950.980.45-0.8-0.980.920.920.690.780.930.970.960.94-0.30.770.60.320.850.960.940.020.960.94
0.870.930.890.920.36-0.95-0.920.921.00.70.760.860.90.930.99-0.230.770.640.560.890.830.780.090.930.92
0.870.930.890.920.36-0.95-0.920.921.00.70.760.860.90.930.99-0.230.770.640.560.890.830.780.090.930.92
0.420.590.510.58-0.21-0.75-0.730.690.70.70.960.50.620.560.65-0.360.990.860.610.90.490.5-0.270.580.53
0.480.680.610.68-0.12-0.76-0.820.780.760.760.960.580.740.660.72-0.280.970.740.540.930.610.61-0.260.680.64
0.870.940.980.970.69-0.69-0.90.930.860.860.50.580.90.960.9-0.20.60.540.130.650.960.920.220.940.96
0.750.980.960.960.41-0.73-0.980.970.90.90.620.740.90.970.92-0.280.710.530.20.820.920.88-0.080.980.97
0.851.01.00.990.56-0.76-0.960.960.930.930.560.660.960.970.96-0.190.660.520.210.760.950.90.081.01.0
0.890.960.940.960.44-0.91-0.940.940.990.990.650.720.90.920.96-0.210.730.610.470.850.870.810.110.960.96
-0.06-0.22-0.18-0.180.120.230.28-0.3-0.23-0.23-0.36-0.28-0.2-0.28-0.19-0.21-0.36-0.46-0.21-0.37-0.22-0.250.25-0.23-0.19
0.510.670.610.68-0.08-0.78-0.80.770.770.770.990.970.60.710.660.73-0.360.850.570.920.60.61-0.210.670.63
0.430.540.480.53-0.1-0.67-0.620.60.640.640.860.740.540.530.520.61-0.460.850.530.760.440.43-0.140.530.5
0.410.230.150.23-0.24-0.79-0.290.320.560.560.610.540.130.20.210.47-0.210.570.530.650.120.120.110.230.2
0.590.780.70.77-0.05-0.89-0.880.850.890.890.90.930.650.820.760.85-0.370.920.760.650.670.65-0.250.780.74
0.840.920.970.970.67-0.66-0.910.960.830.830.490.610.960.920.950.87-0.220.60.440.120.670.990.180.930.93
0.790.860.920.930.64-0.62-0.880.940.780.780.50.610.920.880.90.81-0.250.610.430.120.650.990.170.870.87
0.550.020.120.110.66-0.130.120.020.090.09-0.27-0.260.22-0.080.080.110.25-0.21-0.140.11-0.250.180.170.010.06
0.821.00.980.980.5-0.77-0.970.960.930.930.580.680.940.981.00.96-0.230.670.530.230.780.930.870.011.0
0.841.00.990.990.56-0.75-0.950.940.920.920.530.640.960.971.00.96-0.190.630.50.20.740.930.870.061.0
Click cells to compare fundamentals

Axsome Therapeutics Account Relationship Matchups

Axsome Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets220.5M186.1M(338.4M)331.5M588.2M617.6M
Short Long Term Debt Total19.9M50.1M49.7M94.7M186.4M195.7M
Other Current Liab683.2K8.7M9.3M57.5M95.6M100.4M
Total Current Liabilities24.5M23.4M23.1M96.6M138.9M145.8M
Total Stockholder Equity(175.9M)(278.8M)(409.2M)109.6M191.0M200.5M
Net Debt(200.0M)(133.8M)(36.8M)(106.2M)(199.8M)(189.8M)
Retained Earnings(175.9M)(278.8M)(409.2M)(596.3M)(835.6M)(793.8M)
Accounts Payable10.9M13.5M13.1M38.6M40.7M42.7M
Cash220.0M183.9M86.5M200.8M386.2M405.5M
Cash And Short Term Investments220.0M183.9M86.5M200.8M386.2M405.5M
Common Stock Total Equity3.0K3.7K3.7K3.8K4.3K2.7K
Common Stock Shares Outstanding34.0M37.2M37.6M40.7M45.4M30.1M
Liabilities And Stockholders Equity(134.1M)(206.5M)(338.4M)331.5M588.2M617.6M
Other Current Assets413.1K148.4K45.3K5.6M8.1M8.5M
Other Stockholder Equity(3.7K)392.6M424.8M705.9M1.0B1.1B
Total Liab41.8M72.3M70.8M221.9M397.3M417.1M
Total Current Assets220.4M184.0M86.5M245.6M504.3M529.5M
Short Term Debt2.6M1.2M620.7K425K2.5M1.4M
Common Stock3.7K3.7K3.8K4.4K5K3.2K
Net Tangible Assets178.7M113.8M15.6M39.6M45.5M52.6M
Non Current Assets Total170.5K2.1M1.3M85.8M84.0M88.2M
Non Currrent Assets Other139.9K317.4K322.9K14.7M11.0M11.6M
Other Assets139.9K2.1M(426.1M)14.7M13.2M13.9M
Long Term Debt17.3M48.3M49.1M94.3M178.1M187.0M
Non Current Liabilities Total17.3M48.9M49.1M125.4M258.4M271.3M
Property Plant And Equipment Net30.6K1.8M944.0K1.1M7.6M8.0M
Property Plant And Equipment Gross30.6K1.8M944.0K1.1M7.6M8.0M
Property Plant Equipment30.6K52.6K283.8K1.1M1.3M1.4M
Retained Earnings Total Equity(107.6M)(175.9M)(278.8M)(409.2M)(368.3M)(349.9M)
Long Term Debt Total3.6M17.3M48.3M49.1M56.5M59.3M
Capital Surpluse108.5M354.6M392.6M424.8M488.5M264.6M
Net Invested Capital198.7M162.1M64.7M203.8M369.0M387.5M
Net Working Capital195.9M160.6M63.5M149.1M365.4M383.7M
Capital Stock3.7K3.7K3.8K4.4K5K4.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.